BMS tries out GeneCentric’s Cancer Subtype Platform for Opdivo clinical trials
January 6, 2017Bristol-Myers Squibb (BMS) and GeneCentric Diagnostics have teamed up to explore the possibility of GeneCentric’s Cancer Subtype Platform (CSP) could identify translational biomakers for Opdivo, that could help for future clinical trials.
The two companies in an announcement on Friday said that the colaboration will be funded from BMS, and that GeneCentric will also get support for its new laboratory in Research Triangle Park.
CSP is made to identify biologic subtypes of cancer through an integrated analysis of tumor genomics.
“We are very excited to have Bristol-Myers Squibb as both a collaboration partner and an investor in GeneCentric,” said Myla Lai-Goldman, M.D., CEO of GeneCentric. “Bristol-Myers Squibb is an industry leader in oncology, and we look forward to engaging with them to advance research that may benefit patient prognosis.”
Fouad Namouni, M.D., head of Development, Oncology, Bristol-Myers Squibb, said that GeneCentric’s innovative approach to cancer biomarkers offers an opportunity to accelerate translational and exploratory biomarker research, with the potential to optimize assays that can better inform decisions about patient care and treatments. “We are very pleased to support GeneCentric’s long-term goals as a company and to explore the application of its technology towards more targeted approaches to help patients,” Namouni sad.
